Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot
NLS Pharmaceutics AG, a biopharmaceutical company, is dedicated to the discovery and development of drug therapies to treat rare and complex disorders of the central nervous system. The company is headquartered in Stans, Switzerland.
52W High
$0.04
52W Low
$0.00
MA Status:
50D: Below
200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.15
Valuation
As of 2024-09-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
N/A
Ownership
Source: Overview
Insiders (1–5% typical)
0.00%
Institutions (25–75% balanced)
0.00%
Shares Outstanding
0
Float
1,687,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
As of 2024-09-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
N/A
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
N/A
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentumValue
-0.0001
Previous
-0.0005
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025